Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.21037/tlcr.2016.08.04 http://scihub22266oqcxt.onion/10.21037/tlcr.2016.08.04 C5009078!5009078!27652203     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27652203.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Transl+Lung+Cancer+Res 2016 ; 5 (4): 389-400 Nephropedia Template TP {{tp|p=27652203|t=2016. Targeting angiogenesis in small cell lung cancer |pdf=|usr=}}{{27652203}} gab.com Text Targeting angiogenesis in small cell lung cancer JO: Transl Lung Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=27652203 #FOAvip Small cell lung cancer (SCLC) is a highly aggressive and lethal malignancy. Despite high initial response rates to systemic chemotherapy, the disease eventually relapses; further treatment only modestly improves outcomes and overall survival (OS) for patients with extensive stage disease is less than one year. Little progress has been made during the past decades, with no new drugs approved. Consequently, the development of novel strategies is an unmet need. The inhibition of angiogenesis, a defining characteristic of cancer, has demonstrated modest efficacy in several human malignancies, including non-small cell lung cancer (NSCLC). However, results from clinical trials in SCLC have been disappointing, and no anti-angiogenic agent has received regulatory approval due to lack of clinical efficacy. The elucidation of underlying mechanisms responsible for tumor resistance to angiogenic therapy and the simultaneous blockade of multiple elements that play a role in angiogenesis need to be further explored. Twit Text FOAVip Targeting angiogenesis in small cell lung cancer ????Transl Lung Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=27652203 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27652203 #FOAvip English Wikipedia <ref>{{Cite pmid|27652203}}</ref> Targeting angiogenesis in small cell lung cancer #MMPMID27652203 Stratigos M; Matikas A; Voutsina A; Mavroudis D; Georgoulias V Transl Lung Cancer Res 2016[Aug]; 5 (4): 389-400 PMID27652203show ga Small cell lung cancer (SCLC) is a highly aggressive and lethal malignancy. Despite high initial response rates to systemic chemotherapy, the disease eventually relapses; further treatment only modestly improves outcomes and overall survival (OS) for patients with extensive stage disease is less than one year. Little progress has been made during the past decades, with no new drugs approved. Consequently, the development of novel strategies is an unmet need. The inhibition of angiogenesis, a defining characteristic of cancer, has demonstrated modest efficacy in several human malignancies, including non-small cell lung cancer (NSCLC). However, results from clinical trials in SCLC have been disappointing, and no anti-angiogenic agent has received regulatory approval due to lack of clinical efficacy. The elucidation of underlying mechanisms responsible for tumor resistance to angiogenic therapy and the simultaneous blockade of multiple elements that play a role in angiogenesis need to be further explored. äTargeting angiogenesis in small cell lung cancer (epmc).pdf DeepDyve Pubget Overpricing